WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary cancer immunotherapy products, announced that preclinical data using the Company’s novel drug product, INT230-6, was selected for a poster presentation at the National Cancer Institute’s annual Cancer Immunology and Immunotherapy Meeting. The conference is October 9 -10, 2014 in the Masur Auditorium at the National Institute of Health’s Clinical Center in Bethesda, Maryland. The poster is co-authored by Lewis H. Bender President & CEO of Intensity Therapeutics, Jay A. Berzofsky M.D., Ph.D., Chief of the Vaccine Branch Center for Cancer Research at the NCI and Masaki Terabe, Ph.D. Associate Scientist also at the NCI’s Vaccine Branch.
Help employers find you! Check out all the jobs and post your resume.
